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Study design in valve surgery and
outcome
To the Editor:
The article by Grunkemeier and col-
leagues1 published in the February 2003
issue of the Journal is clearly an important
study demonstrating the role of logistic re-
gression analysis performed on a series of
statistical summaries from different institu-
tions. The authors’ approach toward such
summary of studies may not, however,
have offered the solution to the confusion
present when trying to answer for differ-
ences in complication rates between pros-
thetic valves. They set out to offer expla-
nations for the heterogeneity among the
study series analyzed. However, they did
not address any clinical context in their
explanation for such diverse outcomes with
regard to valve thrombosis, bleeding, and
thromboembolism.
A number of questions need to be ad-
dressed before reaching such a conclusion
from summary of a series. Three important
aspects that were not mentioned include the
etiology of the valve disease, case mix, and
comorbidities. All three factors should be
addressed in the context of which valve is
superior (St Jude vs CarboMedics) in either
mitral or aortic position to that unique pa-
tient’s heart valve biology. No mention
was made of operative variables, including
in-hospital reoperative cases and estimated
blood loss.
To replace a heart valve with a certain
type of prosthesis is a gray zone in the field
of surgery, with as yet little evidence-based
medicine for a valid argument. Differential
understanding, surgical expertise, and insti-
tutional experience still remain the main
determining factors for definitive decision,
except in a clinical trial. A potential draw-
back of analysis of summary statistics in
this case is that it nearly forces the inves-
tigator to ask and attempt to answer the
wrong question (’Is it better to replace with
St Jude or a CarboMedics valve?’) rather
than to ask who can undergo replacement
and, among those, who will benefit from
replacement. This requires analysis of in-
dividual patient data considered more pow-
erful under all circumstances. It may be
more difficult to retrieve such data because
it requires the cooperation of several insti-
tutions and individuals and determination
of common definitions or adjudication
thereof. In a similar context, Lim and co-
workers2 in a randomized controlled trial
showed that no difference existed between
the two valve brands.
When recruiting studies that specifically
address the question of mitral or aortic
valve replacement, strict and valid inclu-
sion criteria need to be adopted. The arti-
cles should include a patient population
description, etiology of disease process,
level of comorbidity, and surgical tech-
nique that are specific and well defined. In
other words, the statistical summary should
detail type of surgical procedure performed
for a specific etiology. Other aspects that
should be taken into account include
whether the addition of coronary artery by-
pass or arrhythmia surgery or another valve
replacement was performed. Moreover, a
more valid and relevant postoperative fol-
low-up will be achieved when including
case series that address in detail preopera-
tive assessment of mitral or aortic valve
pathophysiology.
Before performing a logistic regression,
four essential check points could have been
taken into account. First is the etiology of
mitral and aortic valve disease. Just as the
pathophysiology differs among rheumatic,
ischemic, degenerative, and infectious dis-
ease, so does the outcome. Ischemic etiol-
ogy poses a particularly vexing problem.
Ischemic normal mitral valve is highly
variable. Therefore it is not surprising that
results of replacement with what type of
prosthesis are variable and controversial.
For example, ischemic mitral valve disease
is associated more often with diabetes. Di-
abetes is associated with a hypercoagulable
state.3 So when replacing with either type
of prosthesis, the outcome needs to be ad-
justed for the etiology, not forgetting the
comorbidity. The second main point that
needs to be addressed is how the subval-
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vular tensor apparatus was managed at op-
eration. Left ventricular function is unques-
tionably related to this. At least in the
context of randomized controlled trials,
complete preservation of the apparatus re-
sults in better left ventricular perfor-
mance,4 which also means a lower chance
of thrombus and later embolism develop-
ment.5 This generates another confounding
factor when interpreting the data. Third, the
underlying strategy for anticoagulation
control should be addressed and controlled
for in the inclusion criteria. Finally, the
presence or absence of perioperative atrial
fibrillation is acknowledged as important
by both operating surgeons manufacturers.
It is possible that these factors were
considered; however, for the sake of the
reader, it is necessary to be include them in
the discussion. Such consideration will re-
duce chance-related outcome and broaden
the horizon of the reader when transferring
a statistical critique to clinical reality.




University of Illinois at Chicago
840 Southwood St (CSB suite 518-E)
Chicago, IL 60612
References
1. Grunkemeier GL, Wu Y. “Our complication
rates are lower than theirs:” statistical critique
of heart valve comparisons. J Thorac Cardio-
vasc Surg. 2003;125:290-300.
2. Lim KH, Caputo M, Ascione R, Wild J, West
R, Angelini GD, et al. Prospective random-
ized comparison of CarboMedics and St Jude
Medical bileaflet mechanical heart valve
prostheses: an interim report. J Thorac Car-
diovasc Surg. 2002;123:21-32.
3. Wehinger C, Stollberger C, Langer T,
Schneider B, Finsterer J. Evaluation of risk
factors for stroke/embolism and of complica-
tions due to anticoagulant therapy in atrial
fibrillation. Stroke. 2001;32:2246-52.
4. Yu KL, Sintek CF, Miller DC, Pfeffer TA,
Kochamba GS, Khonsari S, et al. Random-
ized trial comparing partial versus complete
chordal-sparing mitral valve replacement: ef-
fects on left ventricular volume and function.
J Thorac Cardiovasc Surg. 2002;123:707-14.
5. Sharma ND, McCullough PA, Philbin EF,
Weaver WD. Left ventricular thrombus and
subsequent thromboembolism in patients
with severe systolic dysfunction. Chest.
2000;117:314-20.
doi:10.1016/S0022-5223(03)00729-3
Reply to the Editor:
We thank Dr Shuhaiber and colleagues for
their comments on our study comparing
two heart valve models on the basis of
reports from the literature. In describing
the limitations of such comparisons, they
give us another opportunity to stress the
main purpose of our report, which was to
point out precisely these limitations.
The ideal way to compare valve perfor-
mance across multiple studies is to use
risk-adjustment techniques with individual,
patient-level data. But only summary,
study-level information is available from
published reports. We emphasized also that
the simple, weighted-average pooling of
results within valve types is not appropriate
if these results are statistically heteroge-
neous.
A regression approach that does allow
for heterogeneity was used to adjust for
some series-level risk factors: the mean,
maximum, and completeness of follow-up;
bleeding rate, as a surrogate for anticoagu-
lation intensity; mean age; percentage of
male patients; year of publication; number
of valves; and journal impact factor. Three
of the risk factors that Dr Shuhaiber men-
tions, etiology, surgical technique and
atrial fibrillation, were generally not avail-
able in these reports.
It can be seen from the plots of linear-
ized rates that by arbitrarily selecting
groups of studies, the superiority of either
valve in either position for any of the three
outcomes studied can be supported. Be-
cause there is a tendency to perform these
literature comparisons despite the de-
scribed limitations, we used statistical tech-
niques that can account for some of these
limitations. We also stressed the “cautious
interpretation” of even the most carefully
done comparisons.
Gary L. Grunkemeier, PhD
YingXing Wu, MD
Providence Health System
9155 SW Barnes, Suite 33
Portland, OR 97225
doi:10.1016/S0022-5223(03)00730-X
Esophageal perforation during left
atrial radiofrequency ablation: Is the
risk too high?
To the Editor:
The recent article by Doll and colleagues
documents a 1% incidence of esophageal
perforation with intraoperative radiofre-
quency ablation of atrial fibrillation (AF).1
This observation serves as an important
word of caution as we increase the appli-
cation of surgical ablation and design min-
imally invasive procedures to treat AF. In
our exploration of new approaches to
cure AF, we must first follow the edict
“do no harm.” Although AF is an unde-
sirable and dangerous heart rhythm, we
cannot justify major complications in its
treatment.
The esophageal injuries described by
Doll and colleagues resulted from the ap-
plication of a heat-based energy source to
the left atrial endocardium. In each case,
the esophagus, which courses posterior to
the left atrium, suffered a burn with result-
ing esophageal perforation. They note that
this complication has occurred with unipo-
lar radiofrequency and microwave ener-
gies.1,2 It is likely that collateral damage in
general and esophageal injury in particular
will occur occasionally with any heat-
based, endocardial approach to AF ablation
that lacks precise control of lesion depth
and direction.
Safety in AF ablation requires that the
depth of tissue injury be controlled during
ablation; delivery of energy must be fo-
cused and directed to avoid collateral dam-
age. In addition, however, it is generally
accepted that efficacy requires transmural
atrial lesions. There are several promising
modalities that satisfy both of these crite-
ria. Safety may be reliably achieved with
bipolar or epicardial energy delivery. Bipo-
lar radiofrequency devices ablate only the
tissue between the jaws of the clamp, elim-
inating the risk of esophageal injury.3 Epi-
cardial delivery of energy with a shielded,
directional catheter is also an attractive op-
tion. Epicardial ablation using ultrasound
energy may have particular advantages, as
this energy source allows reliable creation
of a lesion that is 10 mm in depth and
design of the ultrasound catheter ensures
directional delivery of energy from the epi-
cardium to the endocardium.
As surgeons explore these technologies
and devise new procedures to cure AF, we
must follow the lead of the group from
Leipzig and share our experiences, whether
they be favorable or unfavorable. This
strategy will facilitate development of ef-
fective and safe procedures to ablate AF.
And this, in turn, will offer the possibility
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